News Focus
News Focus
icon url

BioTechMaven

06/23/17 2:53 PM

#187024 RE: TheBunny #187020

And what's your point exactly? CEO's are replaced all the time and they aren't always happy to be replaced. Quit desperately trying to create stories, digging 10 years back. I wonder what people would find in your life for example if they dug 10 years back?
icon url

Giovanni

06/23/17 3:53 PM

#187056 RE: TheBunny #187020

From: George Evans
Date: Fri, 5 Nov 2010 10:27:51 -0400
Subject: Employment Agreement
==================
Thank You Bunny
===================


Leo

After receiving your e-mails yesterday, I had a chance to reflect on the situation regarding my Employment Agreement. Here is the way I see it:

1. My original Agreement expires three years from the Commitment Date. Since the Commitment Date has not yet occurred, the Agreement has at least three years to go.

2. The Board of Directors of Cellceutix recently approved a two year extension on the same terms as the original Agreement. In the best case for Cellceutix, that means the Agreement would run until December 7, 2012.

3. Cellceutix has no cause to terminate the Agreement.

4. In spite of that, your e-mails from yesterday terminate the agreement. Since there is no cause for the termination and since the Board had only recently approved an extension, this can only be considered a bad faith action to deprive me of the benefit of the Agreement.

5. In parallel, I am exercising my right to terminate the Agreement for Good Reason. Reduction in compensation without my consent is clearly defined as Good Reason in the agreement.

7. In either event, Cellceutix is responsible to me for the full benefit of the Agreement.

6. The net result of your bad faith actions is that Cellceutix is obligated to me for the following:

a. Salary through December 7, 2010 of $900,000.

b. Salary through at least December 7, 2012 of $800,000.

c. Honoring of the stock options previously granted through their full term ( recently extended by Board resolution to five years).

d. Granting of options equal to 1% of the Company’s equity for at least the next two years.

e. Cash bonuses for meeting milestones on IND filing and others as set out in the Agreement.

f. Cellceutix may also be liable for exemplary and/or punitive damages for its bad faith actions.

Regarding accrued salary, I would note that the Company has recently been awarded substantial grants by the Federal Government. I would expect that these funds would be used to satisfy part of the Company’s obligation to me for back salary. Any other use of the funds would be simply another expression of bad faith on the part of the Company.

I expect to receive all the back salary and the future salary that is owed within 30 days of the date of this note. If I have not received the salary, I will be forced to consider other actions.

There are several other items that follow from the termination of the agreement. First, please remove all references to me from the Company’s web site, except to the extent necessary to explain that I am no longer with the Company. This includes contacting the Wall Street Transcript to advise them not to run the interview. As a related item, I have the right to review any disclosures relating to the termination. I assume that you will honor this obligation.

I expect to hear from you promptly that you will live up to your obligations.

Thanks.


Thank you Bunny
icon url

Giovanni

06/23/17 3:57 PM

#187057 RE: TheBunny #187020

Wow this IPIX management does not mind blowing shareholders equity

and has no direction! WOW 7 years later!!!!70 cents!!!
----------------------------------------------------
Former Pfizer Exec Leaves CEO Post at Cellceutix

Ryan McBride
November 10th, 2010
@xconomy
Like Us
Xconomy Boston —
George Evans, a former legal executive for the drug giant Pfizer, has left his post as CEO of Beverly, MA-based Cellceutix (OTCBB:CTIX) because of a dispute about his compensation, the firm said in an SEC filing this week. Evans is demanding that the developer of cancer and autism drugs pay him a total of $1.7 million in back salary and future compensation, according to a copy of an e-mail that the firm filed with U.S. regulators. The board of directors of the firm, which has less than $5,000 in cash, has approved a one-for-50 stock split to improve its ability to raise funds, in part to pay for handling its dispute with Evans. Leo Ehrlich, who has been named interim CEO, did not immediately return a phone call about the situation today.